Synonyms: ER-306323 | ER306323 | Orserdu® | RAD-1901 | RAD1901
elacestrant is an approved drug (FDA & EMA (2023))
Compound class:
Synthetic organic
Comment: Elacestrant is an orally bioactive, selective, non-steroidal dual estrogen receptor degrader (SERD)/selective estrogen receptor modulator (SERM; with antagonist action) [6]. It was developed primarily for antineoplastic potential (via its SERD action at high concentrations) [3]. It has also demonstrated potential to treat the vasomotor symptoms of the menopause with estrogen-like effects detected at low concentrations (SERM activity), but the pharmacology in this setting is very complex [4]. Elacestrant crosses the blood-brain barrier, so is predicted to provide efficacy against breast cancer metastases in the brain.
|
|
Download 2D Structure | |
Canonical SMILES | Download |
Isomeric SMILES | Download |
InChI standard identifier | Download |
InChI standard key | Download |
Molecular structure representations generated using Open Babel